FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Chris Skedgel

Research Profile

Geographic Areas

Nova Scotia

Activities & Behaviors

Cost Benefit Analysis

Concepts & Ideas

Disorders

Breast Neoplasms

Procedures

Organizations

Insurance, Pharmaceutical Services

Chemicals & Drugs

Physiology

Postmenopause

Co-author Network

Publications

TOP 3
Nathan Wd Lamond; Chris Skedgel; Tallal Younis
Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?
Nathan W D Lamond; Lynn N Lethbridge; Daniel Rayson; Chris Skedgel; Tallal Younis
Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer.
Tallal Younis; Chris Skedgel
Adjuvant trastuzumab for breast cancer: uncertainties in clinical and economic evidence following early stopping of the HERA trial.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Chris Skedgel (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Nathan Wd Lamond; Chris Skedgel; Tallal Younis
Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?
Expert review of pharmacoeconomics & outcomes research 2013;13(2):243-50.
2012: Nathan W D Lamond; Lynn N Lethbridge; Daniel Rayson; Chris Skedgel; Tallal Younis
Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer.
Breast cancer research and treatment 2012;133(3):1115-23.
2011: Tallal Younis; Chris Skedgel
Adjuvant trastuzumab for breast cancer: uncertainties in clinical and economic evidence following early stopping of the HERA trial.
PharmacoEconomics 2011;29(5):361-5.
2011: Bryce Kiberd; Chris Skedgel; Ian Alwayn; Kevork M Peltekian
Simultaneous liver kidney transplantation: a medical decision analysis.
Transplantation 2011;91(1):121-7.
2010: Bogdan Superceanu; Sander Veldhuyzen van Zanten; Chris Skedgel; Michael Shepherd; Ingrid Sketris
The rate of prescribing gastrointestinal prophylaxis with either a proton pump inhibitor or an H2-receptor antagonist in Nova Scotia seniors starting nonsteroidal anti-inflammatory drug therapy.
Canadian journal of gastroenterology = Journal canadien de gastroenterologie 2010;24(8):481-8.
2010: C Cameron; Sander Veldhuyzen van Zanten; Chris Skedgel; G Flowerdew; Paul Moayyedi; Ingrid Sketris
Cost-utility analysis of proton pump inhibitors and other gastro-protective agents for prevention of gastrointestinal complications in elderly patients taking nonselective nonsteroidal anti-inflammatory agents.
Alimentary pharmacology & therapeutics 2010;31(12):1354-64.
2009: Chris Skedgel; Daniel Rayson; Tallal Younis
The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2009;12(5):641-8.
2009: John G Hanly; Chris Skedgel; Ingrid Sketris; Charmaine Cooke; Tina Linehan; Kara Thompson; Sander Veldhuyzen van Zanten
Gout in the elderly--a population health study.
The Journal of rheumatology 2009;36(4):822-30.
2008: Tallal Younis; Chris Skedgel
Is trastuzumab a cost-effective treatment for breast cancer?
Expert review of pharmacoeconomics & outcomes research 2008;8(5):433-42.
2008: Tallal Younis; Daniel Rayson; Marlene Sellon; Chris Skedgel
Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100.
Breast cancer research and treatment 2008;111(2):261-7.
2008: A Drucker; Chris Skedgel; K Virik; Daniel Rayson; M Sellon; Tallal Younis
The cost burden of trastuzumab and bevacizumab therapy for solid tumours in Canada.
Current oncology (Toronto, Ont.) 2008;15(3):136-42.
2007: David R Anderson; Susan R Kahn; Marc A Rodger; Michael J Kovacs; Tim Morris; Andrew Hirsch; Eddy Lang; Ian Stiell; George Kovacs; Jonathan Dreyer; Carol Dennie; Yannick Cartier; David Barnes; Erica Burton; Susan Pleasance; Chris Skedgel; Keith O'Rouke; Philip S Wells
Computed tomographic pulmonary angiography vs ventilation-perfusion lung scanning in patients with suspected pulmonary embolism: a randomized controlled trial.
JAMA : the journal of the American Medical Association 2007;298(23):2743-53.
2007: Murray G Brown; S Kirby; Chris Skedgel; John D Fisk; TJ Murray; V Bhan; Ingrid Sketris
How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Neurology 2007;69(15):1498-507.
2007: George Kephart; Chris Skedgel; Ingrid Sketris; Paul Grootendorst; John Hoar
Effect of copayments on drug use in the presence of annual payment limits.
The American journal of managed care 2007;13(6 Pt 2):328-34.
2007: Chris Skedgel; Daniel Rayson; Ron Dewar; Tallal Younis
Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
Breast (Edinburgh, Scotland) 2007;16(3):252-61.
2007: Chris Skedgel; Ron Goeree; Susan Pleasance; Kara Thompson; Bernie O'brien; David Anderson
The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty.
The Journal of bone and joint surgery. American volume 2007;89(4):819-28.
2007: Chris Skedgel; Daniel Rayson; Ron Dewar; Tallal Younis
Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.
Breast cancer research and treatment 2007;101(3):325-33.
2007: Tallal Younis; Daniel Rayson; Ron Dewar; Chris Skedgel
Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(2):293-8.
2006: Neil Hanlon; Chris Skedgel
Cross-district utilization of general hospital care in Nova Scotia: policy and service delivery implications for rural districts.
Social science & medicine (1982) 2006;62(1):145-56.
2005: Ingrid Sketris; George Kephart; Charmaine A Cooke; Chris Skedgel; Pam R McLean-Veysey
Use of physician profiles to influence prescribing of topical corticosteroids.
The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique 2005;12(2):e186-97.
2005: D David Persaud; Steve Jreige; Chris Skedgel; John Finley; Joan Sargeant; Neil Hanlon
An incremental cost analysis of telehealth in Nova Scotia from a societal perspective.
Journal of telemedicine and telecare 2005;11(2):77-84.
2004: Ingrid Sketris; George Kephart; Dawn Frail; Chris Skedgel; Michael J Allen
The effect of deinsuring chlorpropamide on the prescribing of oral antihyperglycemics for Nova Scotia Seniors' Pharmacare beneficiaries.
Pharmacotherapy 2004;24(6):784-91.
2004: Conrad V Fernandez; Chris Skedgel; Charles Weijer
Considerations and costs of disclosing study findings to research participants.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2004;170(9):1417-9.
2003: Chole A Campbell; Charmaine A Cooke; Swarna Weerasinghe; Ingrid Sketris; Pam R McLean-Veysey; Chris Skedgel
Topical corticosteroid prescribing patterns following changes in drug benefit status.
The Annals of pharmacotherapy 2003;37(6):787-93.
2000: Murray G Brown; TJ Murray; Ingrid Sketris; John D Fisk; J C LeBlanc; C E Schwartz; Chris Skedgel
Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates.
International journal of technology assessment in health care 2000;16(3):751-67.
1998: John D Fisk; S A Morehouse; Murray G Brown; Chris Skedgel; TJ Murray
Hospital-based psychiatric service utilization and morbidity in multiple sclerosis.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1998;25(3):230-5.